A single dose of MM120, a pharmaceutical-grade LSD compound, could mark a breakthrough in treating generalized anxiety disorder (GAD), according to a new phase 2b clinical trial published in JAMA.

#LSDTherapy #AnxietyTreatment #MentalHealth #Neuroplasticity #MM120 #Psychiatry

A single 100 μg dose of #MM120 (LSD) significantly reduced #GAD symptoms, with benefits lasting 12 weeks. #psychedelics #mentalhealth
www.hcplive.com/view...

MindMed begins phase 3 study of MM120 for anxiety disorder - PharmaTimes First patient dosed in landmark trial for GAD treatment

#mentalhealth #PsychedelicInspiredMedicine #MindMed #MM120 #anxietydisorder #GeneralisedAnxietyDisorder #GAD #GADtreatment #MM120ODT #lysergideDtartrate #LSD #clinicaltrialparticipants #Voyagestudy #GADpatients #BreakthroughTherapyDesignation #Panoramastudy
pharmatimes.com/news/mindmed...

MindMed’s MM120 ODT Gains UK Innovation Passport for Generalized Anxiety Disorder Treatment Mind Medicine Inc. (MindMed), a clinical-stage biopharmaceutical company, has achieved a significant milestone with the Innovation Passport designation granted by the United Kingdom’s Innovative Licen...

www.linkedin.com/pulse/mindme...

MindMed’s MM120 ODT Gains UK Innovation Passport for Generalized Anxiety Disorder Treatment

kstrategyand.com

#InnovationPassport #MindMed #MM120 #GeneralizedAnxietyDisorder #GAD #MentalHealthInnovation #HealthcareInnovation #Humanteconomy #Humantec #KStrategyand

MindMed Doses First Patient in LSD Anxiety Treatment Trial

Video: youtube.com/shorts/Ewhvi...

#MNMD #MNMDStock #MindMed #MindMedStock #LSDTreatment #MM120 #PsychedelicTreatment #Anxiety #AnxietyTreatment #AnxietyPsychedelics #PsychedelicsAnxiety #LSDAnxietyTreatment #MindMedVoyager